Literature DB >> 11450378

Surfactant replacement therapy--economic impact.

R K Pejaver1, I al Hifzi, S Aldussari.   

Abstract

Surfactant replacement is an effective treatment for neonatal respiratory distress syndrome. (RDS). As widespread use of surfactant is becoming a reality, it is important to assess the economic implications of this new form of therapy. A comparison study was carried out at the Neonatal Intensive Care Unit (NICU) of Northwest Armed Forces Hospital, Saudi Arabia. Among 75 infants who received surfactant for RDS and similar number who were managed during time period just before the surfactant was available, but by set criteria would have made them eligible for surfactant. All other management modalities except surfactant were the same for all these babies. Based on the intensity of monitoring and nursing care required by the baby, the level of care was divided as: Level IIIA, IIIB, Level II, Level I. The cost per day per bed for each level was calculated, taking into account the use of hospital immovable equipment, personal salaries of nursing, medical, ancillary staff, overheads and maintenance, depreciation and replacement costs. Medications used, procedures done, TPN, oxygen, were all added to individual patient's total expenditure. 75 infants in the Surfactant group had 62 survivors. They spent a total of 4300 days in hospital. (av 69.35) Out of which 970 d (av 15.65 per patient) were ventilated days. There were 56 survivors in the non-surfactant group of 75. They had spent a total of 5023 days in the hospital (av 89.69/patient) out of which 1490 were ventilated days (av 26.60 d). Including the cost of surfactant (two doses), cost of hospital stay for each infant taking the average figures of stay would be SR 118, 009.75 per surfactant treated baby and SR 164, 070.70 per non-surfactant treated baby. The difference of 46,061 SR is 39.03% more in non-surfactant group. One Saudi rial = 8 Rs (approx at the time study was carried out.) Medical care cost varies from place to place. However, it is definitely cost-effective where surfactant is concerned. Quality adjusted life years (QALY) for NICU care compares favourably with cost per QALY of several forms of adult health interventions. Audit, both medical and financial, of these services, at regular intervals is essential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11450378     DOI: 10.1007/BF02723239

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  15 in total

1.  Cost of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial.

Authors:  T R Tubman; H L Halliday; C Normand
Journal:  BMJ       Date:  1990-10-13

2.  Cost implications of different approaches to the prevention of respiratory distress syndrome.

Authors:  M Mugford; J Piercy; I Chalmers
Journal:  Arch Dis Child       Date:  1991-07       Impact factor: 3.791

3.  Cost of neonatal intensive and special care.

Authors:  M Connolly; G Fox; G O'Connor; T A Clarke; T G Matthews
Journal:  Ir Med J       Date:  1989-02

4.  Cost-analysis of neonatal intensive and special care.

Authors:  D I Tudehope; W Lee; F Harris; C Addison
Journal:  Aust Paediatr J       Date:  1989-04

5.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

6.  Newborn risk factors and costs of neonatal intensive care.

Authors:  C S Phibbs; R L Williams; R H Phibbs
Journal:  Pediatrics       Date:  1981-09       Impact factor: 7.124

7.  Cost of neonatal care.

Authors:  S Ryan; A Sics; P Congdon
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

8.  Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial.

Authors:  G Enhorning; A Shennan; F Possmayer; M Dunn; C P Chen; J Milligan
Journal:  Pediatrics       Date:  1985-08       Impact factor: 7.124

9.  Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant.

Authors:  Y E Vaucher; L Harker; T A Merritt; M Hallman; K Gist; R Bejar; G P Heldt; D Edwards; M Pohjavuori
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

10.  Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial.

Authors:  M Hallman; T A Merritt; A L Jarvenpaa; B Boynton; F Mannino; L Gluck; T Moore; D Edwards
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

View more
  1 in total

1.  State of health economic evaluation research in Saudi Arabia: a review.

Authors:  Sinaa A Al-Aqeel
Journal:  Clinicoecon Outcomes Res       Date:  2012-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.